Mirum Pharmaceuticals, Inc. (MIRM)
Health Care ยท Pharmaceutical Preparations
Mirum Pharmaceuticals, Inc. (MIRM) is listed on Nasdaq, where its shares have traded since July 18, 2019. SentiSense covers Mirum Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Chris Peetz is its chief executive officer. The company reports 433 employees, and its corporate website is www.mirumpharma.com.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Latest reported results
Mirum Pharmaceuticals, Inc. reported revenue of $185.7 million for Q3 FY2026, up 39.6% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 318 institutions reported holding MIRM, with 71.4 million shares worth $8.4 billion in aggregate. The largest reported holders were Frazier Life Sciences Management, Janus Henderson (Jupiter Topco) and Vanguard. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on MIRM
- MIRM sentiment: whether news and social coverage of Mirum Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- MIRM ownership: all 318 reporting institutions, plus insider and congressional trades.
- MIRM financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Mirum Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases.
What sector is MIRM in?
SentiSense classifies Mirum Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does MIRM stock trade?
Mirum Pharmaceuticals, Inc. (MIRM) is listed on Nasdaq, where its shares have traded since July 18, 2019.
Who is the CEO of Mirum Pharmaceuticals, Inc.?
Chris Peetz is the chief executive officer of Mirum Pharmaceuticals, Inc..